C4 Therapeutics (CCCC) EBIT Margin (2019 - 2025)
Historic EBIT Margin for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to 306.43%.
- C4 Therapeutics' EBIT Margin fell 1225700.0% to 306.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 431.07%, marking a year-over-year decrease of 766300.0%. This contributed to the annual value of 336.15% for FY2024, which is 3336900.0% up from last year.
- As of Q3 2025, C4 Therapeutics' EBIT Margin stood at 306.43%, which was down 1225700.0% from 440.99% recorded in Q2 2025.
- C4 Therapeutics' 5-year EBIT Margin high stood at 75.98% for Q4 2021, and its period low was 1410.21% during Q2 2023.
- Its 5-year average for EBIT Margin is 545.7%, with a median of 402.93% in 2025.
- As far as peak fluctuations go, C4 Therapeutics' EBIT Margin crashed by -12657500bps in 2022, and later soared by 12316200bps in 2024.
- Quarter analysis of 5 years shows C4 Therapeutics' EBIT Margin stood at 75.98% in 2021, then plummeted by -1666bps to 1341.73% in 2022, then rose by 14bps to 1147.72% in 2023, then surged by 37bps to 728.39% in 2024, then soared by 58bps to 306.43% in 2025.
- Its last three reported values are 306.43% in Q3 2025, 440.99% for Q2 2025, and 402.93% during Q1 2025.